3D Medicines (HKG:1244) has filed for patent under the Patent Cooperation Treaty for a key component of its ionizable cationic lipid in the lipid nanoparticles for nucleic acid drug delivery, a Tuesday filing with the Hong Kong bourse said.
The biopharmaceutical company has created an ionizable cationic lipid R&D platform targeting different cell types and organs by using AI to design and screen hundreds of lipid compounds.
The platform synergizes with the development of the firm's self-developed mRNA cancer vaccine projects, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。